Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | MAOB | P27338 | 6/20 | 0.60 |
| ▸ | MAOA | P21397 | 5/20 | 0.60 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.60 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | AS3MT | Q9HBK9 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21245926 | 0.77 | KMT2A (0.71) | MEN1NPC1RAB9AKMT2AMAOB | |
| SCHEMBL4023414 | 0.77 | SRD5A2 (0.78) | MEN1NPC1RAB9AKMT2ASRD5A2 | |
| SCHEMBL4464733 | 0.76 | SRD5A2 (0.81) | MEN1NPC1RAB9AKMT2ASRD5A2 | |
| SCHEMBL6846786 | 0.76 | MAOA (0.80) | MAOBMAOA | |
| SCHEMBL4470968 | 0.75 | SRD5A2 (1.00) | MEN1NPC1RAB9AKMT2ASRD5A2 | |
| SCHEMBL5671185 | 0.75 | MEN1 (0.67) | MEN1NPC1RAB9AKMT2AMAOB | |
| SCHEMBL19559063 | 0.74 | MEN1 (0.66) | MEN1NPC1RAB9AKMT2AMAOB | |
| SCHEMBL5670245 | 0.74 | MEN1 (0.66) | MEN1NPC1RAB9AKMT2AMAOB | |
| SCHEMBL17558914 | 0.74 | NPC1 (0.66) | MEN1NPC1RAB9AKMT2AMAOB | |
| SCHEMBL5670247 | 0.74 | MEN1 (0.66) | MEN1NPC1RAB9AKMT2AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1171428-B1 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2009-06-17 | — | — | EP | disclosed |
| EP-1171428-A4 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2004-09-15 | — | — | EP | disclosed |
| US-6765005-B2 | BACTERICIDES; ENZYME INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2004-07-20 | — | — | US | disclosed |
| US-20030139377-A1 | Fab I inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-07-24 | — | — | US | disclosed |
| US-6503903-B1 | Administering 3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-7-carboxamide derivative | SMITHKLINE BEECHAM CORPORATION | 2003-01-07 | — | — | US | disclosed |
| EP-1171428-A1 | FAB I INHIBITORS | SmithKline Beecham Corporation (US) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000063187-A1 | FAB I INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139377-A1 | Fab I inhibitors | SERPINB1, TFPI, TFPI2 | MEN1 3548/4885NPC1 202/4885RAB9A 2967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.